BioCentury | Nov 26, 2018
Distillery Techniques

Biomarkers

...patients: one with elevated mutation rates in p53 and α thalassemia/mental retardation syndrome X-linked (ATRX; RAD54...
...Zurich, Basel, Switzerland email: jack.kuipers@bsse.ethz.ch CONTACT: Niko Beerenwinkel, same affiliation as above email: niko.beerenwinkel@bsse.ethz.ch Claire Quang ETH Zurich Alpha thalassemia/mental retardation syndrome X-linked (ATRX) (RAD54) Capicua...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

...FDA's list names both targets individually. ASCL1(MASH1) - Achaete-scute family bHLH transcription factor 1; ATRX (RAD54...
BioCentury | Dec 19, 2017
Distillery Techniques

Disease models

...TECHNOLOGY: Transgenics and knockouts Mice with p53 knocked out, ATRX knocked down and both PDGFRA and...
...high-grade gliomas. In mice, embryos engineered in utero for cortical neural progenitor cell-specific p53 knockout, ATRX...
...screen for therapies. DESCRIPTION: Mice with p53 knocked out, α thalassemia/mental retardation syndrome X-linked (ATRX; RAD54...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

...Anderson Cancer Center University of Wisconsin-Madison Unum Therapeutics Inc. 4-1BB ligand (4-1BBL) (TNFSF9) (CD137L) Additional sex combs like 1 (ASXL1) Alpha thalassemia/mental retardation syndrome X-linked B...
BioCentury | May 28, 2015
Distillery Therapeutics

Therapeutics: TAF12 RNA polymerase II TATA box binding protein (TBP)-associated factor (TAF12); nuclear transcription factor Y γ (NFYC); RAD54-like (RAD54L)

...II TATA box binding protein (TBP)-associated factor (TAF12) ; nuclear transcription factor Y γ (NFYC); RAD54-like...
BioCentury | Feb 24, 2011
Distillery Therapeutics

Indication: Cancer

...tumors Multiple endocrine neoplasia I (MEN1; menin); death-domain associated protein (DAXX); a-thalassemia/mental retardation syndrome X-linked (ATRX...
...tumors. In pancreatic neuroendocrine tumors isolated from patients, mutation rates for the MEN1, DAXX and ATRX...
...had a 14% mutation rate. In patients with pancreatic neuroendocrine tumors, MEN1 mutations together with ATRX...
BioCentury | Nov 18, 2010
Targets & Mechanisms

GABAA: better late

...in Nature Neuroscience , that team identified multiple transcription factors-including a-thalassemia/mental retardation syndrome X-linked (ATRX; RAD54...
BioCentury | Sep 11, 2006
Strategy

MediGene chronicles

...for use in other indications D. 4/5/01 - Obtains exclusive European marketing rights from Atrix (ATRX...
BioCentury | Oct 3, 2005
Finance

Tracking QLT

...resolves their dispute with CMS.H. 6/14/04 -QLT announces plans to buy Atrix. The deal includes ATRX's...
BioCentury | Nov 22, 2004
Company News

Atrix, QLT deal

...ATRX share held (see BioCentury, June 21). Using QLTI's Nov. 19 close of $15.42 and ATRX's...
...about $300 million in cash. ATRX Chairman and CEO David Bethune retired. Atrix Laboratories Inc. (ATRX...
Items per page:
1 - 10 of 281